GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Dapsone

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

The long-course leprosy and testing recommendations are preserved historical source content, not certified current guidelines or current service availability.

Check source scope before reading a dose

UCSF - dapsone for Pneumocystis prevention

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Professional

UCSF - dapsone for Pneumocystis prevention

Open original reference

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

For Pneumocystis prevention in adults intolerant of sulfonamides, the institutional dose is 100 mg orally daily without renal adjustment, including the dialysis table. Exclude G6PD deficiency before starting. Dapsone alone does not also prevent toxoplasmosis. This is oral prevention guidance, not a topical-acne dose or a complete Pneumocystis treatment regimen.

RDM30-057-dapsone-1 · Source locator: UCSF - dapsone for Pneumocystis prevention; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/dapsone
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
bd5d0e199b81afd7fee426934b61fdced8d14412634b371dc0d48b98044bddac

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=dapsone&s1=RDM30-057-dapsone&h1=beb3759af54eac6596a94419fbee87f1083bc9a9d5ab9fc0eb9edd310b8478d1